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INTRODUCTION
Familial Mediterranean fever (FMF) is an autosomal
recessive disorder that is characterized by sporadic parox-
ysmal attacks of fever and serosal inflammation. Although
it occurs primarily in ethnic groups originating in the
Mediterranean region, FMF is not restricted to these groups
and is still underdiagnosed in nephrology settings in non-
Mediterranean countries (1).
The disease morbidity is largely associated with recurrent
attacks of pain and fever, and mortality is mainly associated
with amyloidosis and kidney disease (1). The discovery of
colchicine in 1972 led to an effective treatment for FMF in
the prevention of acute attacks and secondary amyloidosis,
significantly increasing the importance of an accurate and
early diagnosis (2). The clinical criteria proposed by Livneh
et al. (3) in 1997 continue to be the gold standard for
diagnosis. However, limitations arise in atypical cases and
in patients of non-Mediterranean origin.
The gene mutated in FMF, MEFV (Mediterranean fever),
was cloned in 1997, shedding light on the disease
pathogenesis and improving the tools for diagnosis (4). In
this scenario, genotype-phenotype correlation studies
revealed specific alleles that were associated with amyloi-
dosis and kidney disease, and mutation-based analysis,
particularly directed toward hot spots, emerged as an
essential approach for diagnosis in atypical cases (5).
CASE DESCRIPTION
A 31-year-old female who emigrated from Syria to Brazil
was admitted due to recurrent episodes of abdominal pain
and fever during the prior four months. Initially ascribed to
pyelonephritis, she received several cycles of antibiotics
without a clinical response. One month prior to admission,
she developed frothy urine and anasarca.
The patient reported a history of episodes of large-joint
arthritis and fever beginning in childhood and acute
abdominal pain that prompted a negative exploratory
laparotomy at age 14. At 16 years old, she entered partial
remission, with mild and less frequent crises of myalgia and
fever. Her family history included consanguinity at the
parent and grandparent levels, episodes of abdominal pain,
fever, and arthritis in two cousins and the paternal grand-
father, and a maternal uncle with similar symptoms who
was on dialysis.
She presented with pallor, anasarca, hypotension, and a
painful abdomen, with palpable liver and spleen. Blood
tests revealed hemoglobin levels of 9.2 g/dL, creatinine
levels of 2.2 mg/dL, albumin levels of 1.6 g/dL and C-
reactive protein levels of 68 mg/L. Antinuclear antibodies
were negative. Complement, liver enzymes and liver
function were normal. Urine and blood cultures and serum
and urine immunofixation electrophoreses were negative, as
was serology for infectious hepatitis and HIV. Urine
analyses showed nephrotic proteinuria (14 g/24 h), gran-
ular casts and no hematuria.
A CT scan revealed enlarged kidneys and hepatospleno-
megaly. A kidney biopsy was performed and showed
secondary amyloidosis as the main finding, which was
associated with signs of acute tubular necrosis and inter-
stitial nephritis (Figures 1 and 2).
In this case, chronic inflammation with abdominal and
joint symptoms and nephrotic syndrome due to secondary
amyloidosis in an Arab patient raised the hypothesis of
FMF, even in the setting of quick renal function decline.
Acute kidney injury may have occurred due to marked
proteinuria, hypoalbuminemia and severe renal hypoperfu-
sion, although in this case, antibiotic toxicity and acute
interstitial nephritis may also have contributed.
The diagnosis of FMF was based on clinical criteria (3)
(Table 1) and further refined by demonstration of M694V
allele homozygosity in the MEFV gene (Figure 3). The
patient received a short course of corticosteroid therapy and
was maintained on colchicine. She showed dramatic
improvement of symptoms and inflammation. The long
period without treatment, however, did not allow for renal
improvement, as determined by a continuous increase in
serum creatinine and the need for renal replacement
therapy six weeks after admission.
DISCUSSION
FMF is prevalent among Arabs and other Mediterranean
ethnicities, but it is rare in the rest of the world. Its
presentation includes crises of self-limiting fever bouts and
elevated acute phase reactants accompanied by arthritis,
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sterile peritonitis, pleurisy, and/or skin rash. The frequency
of episodes varies from once a week to several times a year,
with attacks subsiding spontaneously within one to three
days.
MEFV maps to chromosome 16p13.3, comprises 10 exons
and encodes pyrin/marenostrin, a protein expressed in
granulocytes, monocytes, dendritic cells, and synovial
fibroblasts (6). Pyrin regulates the innate inflammatory
response through its cleavage by caspase-1 followed by NF-
kB activation (7) and interleukin-1b production (8).
Amyloidosis and chronic kidney disease, as detected in
our patient, are less common in FMF and are associated
with a prolonged untreated disease course (5). Continuous
and early treatment with colchicine tends to improve the
attack frequency, duration and intensity and prevents
the development of secondary amyloidosis. Colchicine is
so effective that unresponsiveness prompts evaluation for
compliance or for an alternative diagnosis. Noncompliant
patients represent ,50% of patients who apparently do not
respond to therapy (9). When compliance is assured, other
hereditary autoinflammatory diseases that mimic FMF
should be considered, such as TRAPS (TNF-associated
periodic fever syndrome) and hyperimmunoglobulin D
syndrome, neither of which respond to colchicine (10).
There is no consensus on the treatment of patients who are
true colchicine nonresponders; small series and case reports
have described the potential role of interferon-alpha (11),
thalidomide (12), etanercept (12), infliximab (13) and
interleukin-1 receptor antagonists (14).
FMF manifestations are associated with the nature of
MEFV mutations in different ethnic groups. Five main
mutations (M680I, M694V, M694I and V726A in exon 10
and E148Q in exon 2) are responsible for more than 85% of
FMF cases in the Mediterranean (1,15). Interestingly, homo-
zygosity may not correlate with disease, and some patients
who fulfill clinical criteria do not always have detectable
mutations in MEFV. Our patient was shown to be homo-
zygous for M694V (Figure 3). In fact, when disease is present,
patients with M694V are more severely affected than those
with other mutated alleles, particularly in the homozygous
state, which correlates with amyloidosis and unfavorable
renal prognosis (5,16). The detection of a single mutation in
MEFV, however, is sufficient for diagnostic and therapeutic
purposes when a minimal set of clinical manifestations is
present (17).
The presented case, therefore, underscores the importance
of considering the diagnosis of FMF in regions of the world
where this disease is uncommon, such as Latin America, the
importance of family history for diagnosis, the risks of
missing the diagnosis because of non-renal manifestations,
the potential correlation between genotype and the devel-
opment of end-stage renal disease, the potential conse-
quences of the long-term absence of appropriate therapy,
Figure 1 - Kidney biopsy, hematoxylin-eosin, and light micro-
scopy. Enlarged hypocellular glomerulus with deposits of
amorphous material (arrow). Magnification 300x.
Figure 2 - Congo red staining shows apple-green birefringence
on glomeruli (arrowheads) and tubules (double arrowheads).
Not shown: tubules with degenerative changes, focal areas of
necrosis and areas of interstitial nephritis. Normal blood vessels.
Table 1 - Criteria for the diagnosis of FMF (3).
Requirements for diagnosis of FMF: $1 major criteria, or $2 minor
criteria, or 1 minor criterion plus $5 supportive criteria, or 1 minor
criterion plus $4 of the first 5 supportive criteria.
Major criteria
Typical attacks
1. Peritonitis (generalized)
2. Pleuritic (unilateral) or pericarditis
3. Monoarthritis (hip, knee, ankle)
4. Fever alone
Minor criteria
1-4. Incomplete attacks involving 1 or more of the following sites:
1. Abdomen
2. Chest
3. Joint
4. Exertional leg pain
Supportive criteria
1. Family history of FMF
2. Appropriate ethnic origin
3. Age ,20 years at disease onset
4-7: Features of the attacks
4. Severe, requiring bed rest
5. Spontaneous remission
6. Symptom-free interval
7. Transient inflammatory response, with one or more abnormal test
result(s) for the white blood cell count, erythrocyte sedimentation
rate, serum amyloid A, and/or fibrinogen
8. Episodic proteinuria/hematuria
9. Unproductive laparotomy or removal of white appendix
10. Consaguinity of parents
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and the key role that molecular diagnosis may play,
particularly in equivocal and atypical cases.
AUTHOR CONTRIBUTIONS
Balbo BE worked on the case, analyzed the data and wrote the manuscript.
Silva AA and Amaral AG worked on the case. Malheiros DM performed
the pathological analysis. Onuchic LF analyzed the data and wrote the
manuscript. Barros RT worked on the case and analyzed the data.
REFERENCES
1. Ben-Chetrit E, Touitou I. Familial Mediterranean Fever in the World.
Arthrit Rheum-Arthr. 2009;61(10):1447-53, http://dx.doi.org/10.1002/
art.24458.
2. Goldfinger SE. Colchicine for familial Mediterranean fever. The New
England journal of medicine. 1972;287(25):1302.
3. Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T, et al. Criteria
for the diagnosis of familial Mediterranean fever. Arthritis Rheum.
1997;40(10):1879-85, http://dx.doi.org/10.1002/art.1780401023.
4. Ancient missense mutations in a new member of the RoRet gene family
are likely to cause familial Mediterranean fever. The International FMF
Consortium. Cell. 1997;90(4):797-807.
5. Cazeneuve C, Sarkisian T, Pecheux C, Dervichian M, Nedelec B, Reinert
P, et al. MEFV-gene analysis in Armenian patients with familial
Mediterranean fever: Diagnostic value and unfavorable renal prognosis
of the M694V homozygous genotype - Genetic and therapeutic
implications. Am J Hum Genet. 1999;65(1):88-97, http://dx.doi.org/
10.1086/302459.
6. Tidow N, Chen XG, Muller C, Kawano S, Gombart AF, Fischel-Ghodsian
N, et al. Hematopoietic-specific expression of MEFV, the gene mutated in
familial Mediterranean fever, and subcellular localization of its corre-
sponding protein, pyrin. Blood. 2000;95(4):1451-5.
7. Chae JJ, Wood G, Richard K, Jaffe H, Colburn NT, Masters SL, et al.
The familial Mediterranean fever protein, pyrin, is cleaved by caspase-
1 and activates NF-kappa B through its N-terminal fragment. Blood.
2008;112(5):1794-803, http://dx.doi.org/10.1182/blood-2008-01-
134932.
8. Seshadri S, Duncan MD, Hart JM, Gavrilin MA, Wewers MD. Pyrin
levels in human monocytes and monocyte-derived macrophages
regulate IL-1 beta processing and release. J Immunol. 2007;179(2):1274-
81.
Figure 3 - Top: Family pedigree. Bottom: Individual genotypes and corresponding DNA sequence chromatograms. The nucleotide
position refers to the MEFV mRNA sequence, with the A of the start codon designated as nucleotide 1. WT: wild type. Individual II-1
was not evaluated.
CLINICS 2012;67(6):685-688 Abdominal pain, arthritis and nephrotic syndrome
Balbo BEP et al.
687
9. Peters RS. Non-response to daily colchicine attack suppression in
familial Mediterranean fever. Proceedings, 1st International Conference
on FMF, Jerusalem, Israel 1997. p.8.
10. Drenth JPH, van der Meer JWM. Medical progress: Hereditary periodic
fever. New Engl J Med. 2001;345(24):1748-57, http://dx.doi.org/
10.1056/NEJMra010200.
11. Tunca M, Tankurt E, Akpinar HA, Akar S, Hizli N, Gonen O. The
efficacy of interferon alpha on colchicine-resistant familial
Mediterranean fever attacks: A pilot study. British journal of rheumatol-
ogy. 1997;36(9):1005-8, http://dx.doi.org/10.1093/rheumatology/
36.9.1005.
12. Seyahi E, Ozdogan H, Celik S, Ugurlu S, Yazici H. Treatment options in
colchicine resistant familial Mediterranean fever patients: Thalidomide
and etanercept as adjunctive agents. Clin Exp Rheumatol. 2006;24(5):S99-
S103.
13. Ozgocmen S, Ozcakar L, Ardicoglu O, Kocakoc E, Kaya A, Kiris A.
Familial Mediterranean fever responds well to infliximab: single case
experience. Clinical rheumatology. 2006;25(1):83-7, http://dx.doi.org/
10.1007/s10067-005-1122-9.
14. Belkhir R, Moulonguet-Doleris L, Hachulla E, Prinseau J, Baglin A,
Hanslik T. Treatment of familial Mediterranean fever with anakinra. Ann
Intern Med. 2007;146(11):825-6.
15. Touitou I. The spectrum of Familial Mediterranean Fever (FMF)
mutations. Eur J Hum Genet. 2001;9(7):473-83, http://dx.doi.org/
10.1038/sj.ejhg.5200658.
16. Soylemezoglu O, Arga M, Fidan K, Gonen S, Emeksiz HC, Hasanoglu E,
et al. Unresponsiveness to Colchicine Therapy in Patients with Familial
Mediterranean Fever Homozygous for the M694V Mutation.
J Rheumatol. 2010;37(1):182-9, http://dx.doi.org/10.3899/jrheum.
090273.
17. Booty MG, Chae JJ, Masters SL, Remmers EF, Barham B, Le JM, et al.
Familial Mediterranean Fever With a Single MEFV Mutation Where Is
the Second Hit? Arthritis Rheum-Us. 2009;60(6):1851-61, http://
dx.doi.org/10.1002/art.24569.
Abdominal pain, arthritis and nephrotic syndrome
Balbo BEP et al.
CLINICS 2012;67(6):685-688
688
